BioSpace News Archive

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office has granted a patent covering its proprietary platform technology for the oral administration of Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies.

Dr. Reddy’s Laboratories Ltd. announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® approved by the U.S. Food and Drug Administration.

Immuron Limited, an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to provide shareholders with an update on the progress made to date on the company’s research collaboration with the Naval Medical Research Center previously announced in October 2019.

The Tuberous Sclerosis Alliance and Seizure Tracker™ announced a partnership to promote data sharing and biosample collection from people with tuberous sclerosis complex, a rare genetic condition that causes tumors to form in vital organs.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced that its subsidiary, MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”) has entered into an agreement to supply pharmaceutical-quality (GMP certified), formulated cannabis oil products to Beacon Medical Australia Pty. Ltd.

Emerald Health Therapeutics, Inc. reported financial results for the quarter and ended March 31, 2020. Full versions of the Company’s unaudited condensed interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com.

CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard of care alone in a 206-patient trial

Curatio, a fast-growing digital health company addressing the massive problem of delivering patient support, engagement and education at scale, is pleased to announce the appointment of Paul Cowley as Vice President of Data Insights and Partner Solutions. With more than 25 years experience leveraging technology and data science to

Today, Steve Shum , Chief Executive Officer of INVO Bioscience, Inc. (OTCQB: INVO) (OTCQB: INVOD), a medical device company focused on creating alternative treatments for patie

Progenity, Inc . (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Progenity, are